Related Experiment Video

Updated: May 8, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

PLA2R1 mediates tumor suppression by activating JAK2

David Vindrieux1, Arnaud Augert, Christophe A Girard

  • 1Authors' Affiliations: Inserm U1052, Centre de Recherche en Cancérologie de Lyon; CNRS UMR5286; Centre Léon Bérard; Université de Lyon, Lyon; UMR8161, CNRS/Universités de Lille 1 et 2; Institut de Pharmacologie Moléculaire et Cellulaire, UMR7275, CNRS and Université de Nice-Sophia Antipolis, Valbonne; INSERM U916, Bergonié Cancer Institute, Université Bordeaux, Bordeaux; and Institut de Pathologie, CHRU, Faculté de Médecine, Université de Lille; INSERM U837, Jean-Pierre Aubert Research Center, Team 5, Lille; Department of Medicine, University of Washington, Seattle, Washington.

Cancer Research
|September 7, 2013
PubMed

Insights

The phospholipase A2 receptor (PLA2R1) acts as a tumor suppressor by preventing oncogene-induced senescence escape. Its depletion promotes tumorigenesis, unexpectedly through activating the JAK2 pathway.

Area of Science:

  • Molecular biology
  • Oncology
  • Cellular senescence

Background:

  • The physiological role of phospholipase A2 receptor (PLA2R1) is largely unknown.
  • PLA2R1 is implicated in replicative senescence, a proliferation arrest mechanism.
  • Its downstream signaling and role in cancer remain uncharacterized.

Purpose of the Study:

  • To investigate the role of PLA2R1 in oncogene-induced senescence (OIS) and tumorigenesis.
  • To elucidate the downstream signaling pathways regulated by PLA2R1 in cancer.
  • To determine the physiological function of PLA2R1 as a tumor suppressor.

Main Methods:

  • In vitro studies assessing PLA2R1 depletion and oncogenic transformation.
  • In vivo studies using genetically modified mice (PLA2R1-deficient) and RAS-induced tumorigenesis models.
  • Analysis of JAK2 pathway activation and its role in PLA2R1-mediated effects.

Main Results:

  • PLA2R1 depletion facilitates escape from OIS, promoting oncogenic cell transformation in vitro.
  • PLA2R1-deficient mice exhibit increased sensitivity to RAS-induced tumorigenesis due to impaired OIS.
  • PLA2R1 unexpectedly activates JAK2 signaling, and this activation is crucial for its tumor-suppressive function.

Conclusions:

  • PLA2R1 functions as a tumor suppressor by inhibiting OIS escape.
  • PLA2R1's tumor-suppressive role is mediated via activation of the JAK2 pathway.
  • This study uncovers a novel, counterintuitive mechanism of tumor suppression involving PLA2R1 and JAK2.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...